Using genetic variation for establishing causality of cardiovascular risk factors: Overcoming confounding and reverse causality

Netherlands Heart Journal

Volumn 22, Issue 4, 2014, Pages 186-189

  Smit, R A J ^a   Trompet, S ^a   de Craen, A J M ^a   Jukema, J W ^a,b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ROYAL NETHERLANDS ACADEMY OF ARTS AND SCIENCES   (Netherlands)

Author keywords

Cardiovascular risk assessment; Genetics; Instrumental variable analysis; Mendelian randomization

Indexed keywords

APOLIPOPROTEIN E; C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; SECRETORY PHOSPHOLIPASE A2;

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; GENETIC ASSOCIATION; GENETIC EPIDEMIOLOGY; GENETIC VARIABILITY; HEART INFARCTION; HUMAN; INSTRUMENTAL VARIABLE ANALYSIS; MENDELIAN RANDOMIZATION ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84896461111     PISSN: 15685888     EISSN: 18766250     Source Type: Journal    
DOI: 10.1007/s12471-014-0534-z     Document Type: Article

References (26)

1. Mendis S, Puska P, Norrving B, editors. Global atlas on cardiovascular disease prevention and control. Geneva: World Health Organization; 2011. Available from: www.who.int/cardiovascular_ diseases/publications/atlas_cvd/en/.
2. Kannel WB, Dawber TR, Kagan A, et al. Factors of risk in the development of coronary heart disease-six year follow-up experience. The Framingham Study. Ann Intern Med. 1961;55:33-50.
3. Wilson PW, D'Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. Circulation. 1998; 97 (18): 1837-47.
4. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288(3):321-33.
5. Gabriel SR, Carmona L, Roque M, et al. Hormone replacement therapy for preventing cardiovascular disease in post-menopausal women. Cochrane Database Syst Rev. 2005;(2):CD002229.
6. Lawlor DA, Davey Smith G, Kundu D, et al. Those confounded vitamins: what can we learn from the differences between observational versus randomised trial evidence? Lancet. 2004;363(9422): 1724-7.
7. Lawlor DA, Harbord RM, Sterne JA, et al. Mendelian randomization: using genes as instruments for making causal inferences in epidemiology. Stat Med. 2008;27(8):1133-63.
8. Gray R, Wheatley K. How to avoid bias when comparing bone marrow transplantation with chemotherapy. Bone Marrow Transplant. 1991; 7 Suppl 3:9-12.
9. Greenland S. An introduction to instrumental variables for epidemiologists. Int J Epidemiol. 2000;29(4):722-9.
10. Katan MB. Apolipoprotein E, isoforms, serum cholesterol, and cancer. Lancet. 1986;1(8479):507-8.
11. Mendel G. Experiments in plant hybridization. 1865. Available from: www.mendelweb.org/archive/Mendel.Experiments.txt.
12. Davey Smith G, Ebrahim S. What can mendelian randomisation tell us aboutmodifiable behavioural and environmental exposures?BMJ. 2005;330(7499):1076-9.
13. Koenig W, Khuseyinova N. Lipoprotein-associated and secretory phospholipase A2 in cardiovascular disease: the epidemiological evidence. Cardiovasc Drugs Ther. 2009;23(1):85-92.
14. Nicholls SJ, Kastelein JJ, Schwartz GG, et al. Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial. JAMA. 2014;311(3):252-62.
15. Holmes MV, Simon T, Exeter HJ, et al. Secretory phospholipase A(2)-IIA and cardiovascular disease: a Mendelian randomization study. J Am Coll Cardiol. 2013;62(21):1966-76.
16. Zacho J, Tybjaerg-Hansen A, Jensen JS, et al. Genetically elevated Creactive protein and ischemic vascular disease. N Engl J Med. 2008;359(18):1897-908.
17. Trompet S, Jukema JW, Katan MB, et al. Apolipoprotein e genotype, plasma cholesterol, and cancer: a Mendelian randomization study. Am J Epidemiol. 2009;170(11):1415-21.
18. Pierce BL, Ahsan H, Vanderweele TJ. Power and instrument strength requirements for Mendelian randomization studies using multiple genetic variants. Int J Epidemiol. 2011;40(3):740-52.
19. Burgess S, Thompson SG. Use of allele scores as instrumental variables for Mendelian randomization. Int J Epidemiol. 2013;42(4):1134-44.
20. Teslovich TM, Musunuru K, Smith AV, et al. Biological, clinical and population relevance of 95 loci for blood lipids. Nature. 2010;466(7307):707-13.
21. Ehret GB, Munroe PB, Rice KM, et al. Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature. 2011;478(7367):103-9.
22. Speliotes EK, Willer CJ, Berndt SI, et al. Association analyses of 249, 796 individuals reveal 18 new loci associated with body mass index. Nat Genet. 2010;42(11):937-48.
23. Dehghan A, Dupuis J, Barbalic M, et al. Meta-analysis of genome-wide association studies in >80 000 subjects identifies multiple loci for C-reactive protein levels. Circulation. 2011;123(7):731-8.
24. Voight BF, Peloso GM, Orho-Melander M, et al. Plasma HDL cholesterol and risk of myocardial infarction: a Mendelian randomisation study. Lancet. 2012;380(9841):572-80.
25. Lieb W, Jansen H, Loley C, et al. Genetic predisposition to higher blood pressure increases coronary artery disease risk. Hypertension. 2013;61(5):995-1001.
26. Willer CJ, Schmidt EM, Sengupta S, et al. Discovery and refinement of loci associated with lipid levels. Nat Genet. 2013;45(11):1274-83.